France 2030 supports KÔL’s clinical study in AMD Laboratoires KÔL has received French government funding under France 2030 to support SKY2, a clinical research programme dedicated to AMD. The study is evaluating aganirsen, an antisense oligonucleoti... Press
KÔL x Kubota: a new partnership for patients with Stargardt disease KÔL is very proud to announce its collaboration with Kubota Vision Inc. through the signing of a supply and licence agreement to facilitate access in France to emixustat, a drug candidate for the trea... Press